NCT07158918 - ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 6, 2025

Primary Completion Date

December 2, 2027

Study Completion Date

December 2, 2027

Conditions

Solid Tumors

Interventions

DRUG

ABL103

IV infusion

DRUG

KEYTRUDA® (pembrolizumab)

IV infusion

DRUG

Taxane

IV infusion

Trial Locations (6)

NOT_YET_RECRUITING

PASO Medical, Frankston

RECRUITING

Seoul National University Bundang Hospital, Seongnam

NOT_YET_RECRUITING

UH Cleveland Medical Center, Cleveland

RECRUITING

Seoul National University Hospital, Seoul

NOT_YET_RECRUITING

Asan Medical Center, Seoul

NOT_YET_RECRUITING

Samsung Medical Center, Seoul